New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
08:39 EDTABMDAbiomed strength should be used as a selling opportunity, says Northland
Northland Securities recommends using any strength today as a selling opportunity and said the FDA close-out letter has nothing to do with the Department of Justice/Hippa investigation on off-label marketing. Shares are Underperform rated with a $9 price target.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 17, 2015
08:00 EDTABMDAbiomed price target raised to $72 from $60 at Leerink
Subscribe for More Information
08:00 EDTABMDAbiomed price target raised to $72 from $60 at Leerink
Leerink raised its price target for Abiomed shares to $72 saying it believes recent adoption momentum is sustainable as the company continues to penetrate the emergent and high risk percutaneous coronary intervention patient population. It reiterates an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use